News Article

EssilorLuxottica’s unveiling of Stellest 2.0 spectacle lenses at China’s International Import Expo on November 5 points to a data-driven, non-invasive alternative to atropine drops or refractive surgery, potentially redirecting paediatric eye-care pathways.

Med-tech players should note the lens-plus-sensor model, which marries diagnostics, compliance analytics, and hardware – is an architecture transferrable to other chronic-care settings.

EssilorLuxottica is a global leader in the design, manufacturing and distribution of advanced vision care products, eyewear and med-tech solutions.

Its second-generation lens delivers materially slows axial eye elongation, extending the evidence base that secured the original Stellest the first FDA authorisation for a myopia-control lens.